Research programme: autoimune disorders therapies - 4C Biomed
Alternative Names: Alpha 4CB-(3-7); α4CB-(3-7)Latest Information Update: 05 Oct 2021
At a glance
- Originator 4C Biomed
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 30 Sep 2021 Research programme: autoimune disorders - 4C Biomed is available for licensing as of 30 Sep 2021. https://4cbiomed.com/collaborations/
- 30 Sep 2021 Early research in Autoimmune disorders in United Kingdom (4C Biomed pipeline, September 2021)